Patient Characteristics Over Time
| Time . | Factor VIII Activity (IU/mL) . | Inhibitor (BU/mL) . | Half-Life . | Bleeding Pattern . |
|---|---|---|---|---|
| . | . | . | (h) . | . |
| Before 1980 | 0.20 | 0.0 | Mild | |
| 1980 | 0.01 | 22 | 2-3 | Severe muscle hematomas |
| 1981 | 0.08 | 1.2 | Mild | |
| 1992 | 0.14 | 0.7 | Mild | |
| 1994 | 0.14 | 0.7 | 5.5 | Mild |
| 1995 | 0.14 | 0.4 | Mild |
| Time . | Factor VIII Activity (IU/mL) . | Inhibitor (BU/mL) . | Half-Life . | Bleeding Pattern . |
|---|---|---|---|---|
| . | . | . | (h) . | . |
| Before 1980 | 0.20 | 0.0 | Mild | |
| 1980 | 0.01 | 22 | 2-3 | Severe muscle hematomas |
| 1981 | 0.08 | 1.2 | Mild | |
| 1992 | 0.14 | 0.7 | Mild | |
| 1994 | 0.14 | 0.7 | 5.5 | Mild |
| 1995 | 0.14 | 0.4 | Mild |
Plasma levels of factor VIII and inhibitor were determined as described in the Materials and Methods. The factor VIII antigen levels (measured by an enzyme-linked immunosorbent assay using two different MoAbs directed towards the light chain of factor VIII) were 0.08 IU/mL in the plasma samples of 1992, 1994, and 1995. No cross-reactivity of the inhibitor against porcine factor VIII was observed in 1992.